SPY423.45+0.34 0.08%
DIA339.31-0.14 -0.04%
IXIC14,296.54+43.27 0.30%

ClearPoint Neuro Q1 Loss Flat Amid Higher Revenue, Gets FDA Nod for SmartFrame Array -- Stock Jumps 8% After-Hours

05/11/2021 13:45

05:39 PM EDT, 05/11/2021 (MT Newswires) -- ClearPoint Neuro (CLPT) on Tuesday reported a net loss of $0.13 per share in Q1, flat from a year ago, as revenue grew 29% to $4.0 million over the same period.

Two analysts in a Capital IQ poll projected a net loss of $0.15 per share on revenue of $3.25 million.

For the full year 2021, the company expects revenue of $16.0 to $17.5 million, against the Street estimate of $15.83 million.

The company also said it has secured approval from the US Food and Drug Administration for SmartFrame Array, its new and flexible navigation system for use in the MRI Suite and operating room.

Price: 19.04, Change: +1.38, Percent Change: +7.81